BIIB
$183.77+0.51 (+0.28%)
Biogen Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for ...
Recent News
Biogen (BIIB) Valuation Check As New SMA Data And Phase 3 Plans Draw Fresh Growth Focus
Biogen (BIIB) has put fresh attention on its spinal muscular atrophy pipeline after sharing new Phase 1b salanersen data showing sustained neurodegeneration biomarker reductions and motor milestone gains, along with detailed plans for three Phase 3 studies. See our latest analysis for Biogen. Against this backdrop of fresh SMA data, Biogen’s share price has moved to US$183.26, with a 6.86% 90 day share price return and a 27.67% 1 year total shareholder return, while longer term total...
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build
Denali Therapeutics (NASDAQ:DNLI) executives outlined near-term regulatory milestones, commercial launch preparations, and a broadening pipeline during a discussion hosted by Leerink Partners analyst Marc Goodman. Chief Executive Officer Ryan Watts and Chief Commercial Officer Katie Peng focused on
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference
Biogen (NASDAQ:BIIB) outlined its growing “West Coast Hub” and development plans for felzartamab, an anti-CD38 antibody being studied across multiple kidney-related immunology indications, during a conference discussion between Leerink Partners analyst Marc Goodman and Utpal Patel, Biogen’s Head of